Share Price and Basic Stock Data
Last Updated: January 21, 2026, 4:58 pm
| PEG Ratio | 6.28 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Bal Pharma Ltd operates in the pharmaceuticals industry, focusing on the production and distribution of various medicinal products. As of the latest reporting period, the company’s stock price stood at ₹68.3, with a market capitalization of ₹109 Cr. Revenue from operations for the year ending March 2024 recorded a robust ₹339 Cr, an increase from ₹304 Cr in March 2023. This upward trend reflects a consistent growth trajectory, with total sales for the trailing twelve months (TTM) at ₹295 Cr. Quarterly sales showed fluctuations, peaking at ₹94.63 Cr in March 2024, indicating a potential recovery in demand after a dip to ₹70.39 Cr in June 2023. The operating profit margin (OPM) has also shown improvement, standing at 10.14% in March 2024, compared to 8% in March 2023, underscoring the company’s ability to enhance profitability amidst varying sales volumes.
Profitability and Efficiency Metrics
Bal Pharma’s profitability metrics illustrate a mixed performance. The company’s net profit for the year ending March 2024 was recorded at ₹7 Cr, consistent with the previous fiscal year, while the earnings per share (EPS) stood at ₹4.54 for March 2025. The return on equity (ROE) was reported at 9.32%, which is within a reasonable range compared to typical sector standards. However, the operating profit margin (OPM) of 10.14% in March 2024, while improved, remains lower than many industry peers, indicating room for operational efficiencies. The interest coverage ratio (ICR) stood at 1.88x, suggesting that the company comfortably meets its interest obligations. However, the cash conversion cycle (CCC) of 161 days indicates potential inefficiencies in managing working capital, highlighting a need for improvement in inventory and receivables management.
Balance Sheet Strength and Financial Ratios
Bal Pharma’s balance sheet reveals a total borrowing of ₹155 Cr against reserves of ₹62 Cr, indicating a relatively high leverage ratio. The total debt to equity ratio stood at 1.94x, which is elevated compared to industry norms, suggesting potential financial risk in adverse market conditions. The current ratio of 1.07 indicates that the company maintains an adequate liquidity position to cover short-term liabilities. Additionally, the book value per share has increased to ₹48.63 as of March 2025, reflecting a growing asset base. The company’s fixed assets have also risen to ₹87 Cr, indicating ongoing investments in infrastructure. However, the decline in the return on capital employed (ROCE) to 10% in March 2025 from 12% in the previous year raises concerns about the efficiency of capital utilization.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Bal Pharma shows a stable yet concentrated ownership structure, with promoters holding 50.87% of the equity as of September 2025. The public shareholding constitutes 48.91%, while foreign institutional investors (FIIs) hold a marginal 0.23%. This concentration of ownership may reflect strong confidence from the management but could also raise concerns about limited market participation. The total number of shareholders decreased from 16,466 in December 2022 to 15,774 in September 2025, indicating a decline in investor interest. However, the slight increase in FII holdings from 0.18% in December 2022 to 0.23% in September 2025 suggests a growing recognition of the company’s potential among foreign investors. This trend may bolster investor confidence moving forward.
Outlook, Risks, and Final Insight
Looking ahead, Bal Pharma faces both opportunities and challenges. The company’s ability to enhance its operational efficiency and reduce the cash conversion cycle will be critical for sustaining profitability. Potential risks include the high leverage reflected in a debt-to-equity ratio of 1.94x, which could strain financial resources in a downturn. Furthermore, fluctuations in quarterly sales highlight the volatility in demand, necessitating strategic planning to stabilize revenues. If Bal Pharma can successfully streamline operations and manage its debt levels, it may potentially unlock value for shareholders. However, failure to address these risks could hinder growth and affect market confidence. Overall, while the company’s fundamentals show promise, diligent management of operational and financial risks will be essential for its long-term success.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 120 Cr. | 95.1 | 205/84.3 | 26.5 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,638 Cr. | 334 | 479/192 | 75.4 | 24.3 | 0.20 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.2 Cr. | 43.4 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 58.7 Cr. | 40.1 | 41.0/17.0 | 140 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,411.82 Cr | 1,082.17 | 50.55 | 202.18 | 0.38% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 75.31 | 76.62 | 82.45 | 70.39 | 92.54 | 81.66 | 94.63 | 74.36 | 73.69 | 73.15 | 81.88 | 65.87 | 74.02 |
| Expenses | 69.53 | 70.47 | 74.29 | 63.95 | 84.84 | 73.87 | 85.03 | 67.89 | 66.00 | 65.40 | 74.24 | 59.81 | 68.29 |
| Operating Profit | 5.78 | 6.15 | 8.16 | 6.44 | 7.70 | 7.79 | 9.60 | 6.47 | 7.69 | 7.75 | 7.64 | 6.06 | 5.73 |
| OPM % | 7.67% | 8.03% | 9.90% | 9.15% | 8.32% | 9.54% | 10.14% | 8.70% | 10.44% | 10.59% | 9.33% | 9.20% | 7.74% |
| Other Income | 0.05 | 0.46 | 0.19 | 0.16 | 0.14 | 0.10 | 2.45 | 0.82 | -0.20 | 0.51 | 1.08 | 0.72 | 1.12 |
| Interest | 2.86 | 3.11 | 3.85 | 3.64 | 3.82 | 3.66 | 4.14 | 4.24 | 3.65 | 5.01 | 3.95 | 4.05 | 3.86 |
| Depreciation | 2.37 | 2.45 | 2.09 | 2.53 | 2.42 | 2.96 | 2.16 | 2.43 | 2.48 | 2.69 | 2.18 | 2.52 | 2.27 |
| Profit before tax | 0.60 | 1.05 | 2.41 | 0.43 | 1.60 | 1.27 | 5.75 | 0.62 | 1.36 | 0.56 | 2.59 | 0.21 | 0.72 |
| Tax % | 78.33% | 43.81% | 32.78% | 79.07% | 39.38% | 33.07% | 3.65% | 58.06% | 23.53% | 7.14% | -108.88% | 0.00% | 0.00% |
| Net Profit | 0.12 | 0.59 | 1.62 | 0.09 | 0.97 | 0.85 | 5.53 | 0.26 | 1.04 | 0.52 | 5.41 | 0.21 | 0.72 |
| EPS in Rs | 0.07 | 0.36 | 1.02 | 0.05 | 0.61 | 0.56 | 3.46 | 0.16 | 0.65 | 0.30 | 3.41 | 0.13 | 0.45 |
Last Updated: January 2, 2026, 8:31 am
Below is a detailed analysis of the quarterly data for Bal Pharma Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 74.02 Cr.. The value appears strong and on an upward trend. It has increased from 65.87 Cr. (Jun 2025) to 74.02 Cr., marking an increase of 8.15 Cr..
- For Expenses, as of Sep 2025, the value is 68.29 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 59.81 Cr. (Jun 2025) to 68.29 Cr., marking an increase of 8.48 Cr..
- For Operating Profit, as of Sep 2025, the value is 5.73 Cr.. The value appears to be declining and may need further review. It has decreased from 6.06 Cr. (Jun 2025) to 5.73 Cr., marking a decrease of 0.33 Cr..
- For OPM %, as of Sep 2025, the value is 7.74%. The value appears to be declining and may need further review. It has decreased from 9.20% (Jun 2025) to 7.74%, marking a decrease of 1.46%.
- For Other Income, as of Sep 2025, the value is 1.12 Cr.. The value appears strong and on an upward trend. It has increased from 0.72 Cr. (Jun 2025) to 1.12 Cr., marking an increase of 0.40 Cr..
- For Interest, as of Sep 2025, the value is 3.86 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 4.05 Cr. (Jun 2025) to 3.86 Cr., marking a decrease of 0.19 Cr..
- For Depreciation, as of Sep 2025, the value is 2.27 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 2.52 Cr. (Jun 2025) to 2.27 Cr., marking a decrease of 0.25 Cr..
- For Profit before tax, as of Sep 2025, the value is 0.72 Cr.. The value appears strong and on an upward trend. It has increased from 0.21 Cr. (Jun 2025) to 0.72 Cr., marking an increase of 0.51 Cr..
- For Tax %, as of Sep 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00%.
- For Net Profit, as of Sep 2025, the value is 0.72 Cr.. The value appears strong and on an upward trend. It has increased from 0.21 Cr. (Jun 2025) to 0.72 Cr., marking an increase of 0.51 Cr..
- For EPS in Rs, as of Sep 2025, the value is 0.45. The value appears strong and on an upward trend. It has increased from 0.13 (Jun 2025) to 0.45, marking an increase of 0.32.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:35 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 179 | 187 | 198 | 229 | 211 | 225 | 171 | 251 | 281 | 304 | 339 | 303 | 295 |
| Expenses | 161 | 170 | 183 | 214 | 194 | 207 | 166 | 226 | 257 | 279 | 308 | 273 | 268 |
| Operating Profit | 18 | 17 | 15 | 15 | 17 | 18 | 5 | 25 | 24 | 25 | 31 | 30 | 27 |
| OPM % | 10% | 9% | 7% | 6% | 8% | 8% | 3% | 10% | 9% | 8% | 9% | 10% | 9% |
| Other Income | 1 | 1 | 1 | 3 | 2 | 1 | 2 | 1 | 5 | 1 | 3 | 2 | 3 |
| Interest | 7 | 7 | 6 | 8 | 9 | 13 | 13 | 12 | 11 | 12 | 15 | 17 | 17 |
| Depreciation | 5 | 7 | 7 | 6 | 7 | 6 | 8 | 10 | 9 | 9 | 10 | 10 | 10 |
| Profit before tax | 7 | 5 | 3 | 3 | 3 | -0 | -14 | 4 | 9 | 5 | 9 | 5 | 4 |
| Tax % | 23% | 25% | 90% | 114% | 87% | -1,175% | -5% | -15% | 38% | 45% | 18% | -41% | |
| Net Profit | 5 | 4 | 1 | -0 | 0 | 2 | -13 | 5 | 6 | 3 | 7 | 7 | 7 |
| EPS in Rs | 4.56 | 2.82 | 1.10 | 1.24 | 1.96 | 2.67 | -8.62 | 3.20 | 3.78 | 1.64 | 4.68 | 4.53 | 4.29 |
| Dividend Payout % | 22% | 35% | 91% | 81% | 51% | 37% | 0% | 31% | 26% | 61% | 26% | 26% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -20.00% | -75.00% | -100.00% | -750.00% | 138.46% | 20.00% | -50.00% | 133.33% | 0.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | -55.00% | -25.00% | -650.00% | 888.46% | -118.46% | -70.00% | 183.33% | -133.33% |
Bal Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 9 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 12% |
| 3 Years: | 3% |
| TTM: | -14% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 21% |
| 3 Years: | 13% |
| TTM: | -5% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 14% |
| 3 Years: | -3% |
| 1 Year: | -37% |
| Return on Equity | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 9% |
| 3 Years: | 9% |
| Last Year: | 10% |
Last Updated: September 5, 2025, 12:20 am
Balance Sheet
Last Updated: December 4, 2025, 1:00 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 11 | 13 | 13 | 14 | 14 | 14 | 14 | 15 | 15 | 16 | 16 | 16 | 16 |
| Reserves | 39 | 42 | 42 | 48 | 51 | 52 | 38 | 39 | 44 | 48 | 56 | 62 | 62 |
| Borrowings | 51 | 49 | 89 | 93 | 110 | 124 | 118 | 110 | 104 | 131 | 140 | 150 | 155 |
| Other Liabilities | 54 | 59 | 67 | 78 | 86 | 71 | 68 | 76 | 98 | 116 | 108 | 108 | 116 |
| Total Liabilities | 155 | 164 | 211 | 233 | 260 | 261 | 238 | 240 | 261 | 311 | 320 | 336 | 349 |
| Fixed Assets | 55 | 52 | 56 | 60 | 71 | 70 | 71 | 69 | 67 | 76 | 80 | 87 | 92 |
| CWIP | 0 | 1 | 4 | 2 | 0 | 4 | 3 | 0 | 2 | 0 | 0 | 3 | 3 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 2 | 0 |
| Other Assets | 99 | 111 | 151 | 172 | 188 | 187 | 164 | 172 | 192 | 235 | 233 | 244 | 253 |
| Total Assets | 155 | 164 | 211 | 233 | 260 | 261 | 238 | 240 | 261 | 311 | 320 | 336 | 349 |
Below is a detailed analysis of the balance sheet data for Bal Pharma Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 16.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 16.00 Cr..
- For Reserves, as of Sep 2025, the value is 62.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 62.00 Cr..
- For Borrowings, as of Sep 2025, the value is 155.00 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from 150.00 Cr. (Mar 2025) to 155.00 Cr., marking an increase of 5.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 116.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 108.00 Cr. (Mar 2025) to 116.00 Cr., marking an increase of 8.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 349.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 336.00 Cr. (Mar 2025) to 349.00 Cr., marking an increase of 13.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 92.00 Cr.. The value appears strong and on an upward trend. It has increased from 87.00 Cr. (Mar 2025) to 92.00 Cr., marking an increase of 5.00 Cr..
- For CWIP, as of Sep 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 3.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2.00 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 2.00 Cr..
- For Other Assets, as of Sep 2025, the value is 253.00 Cr.. The value appears strong and on an upward trend. It has increased from 244.00 Cr. (Mar 2025) to 253.00 Cr., marking an increase of 9.00 Cr..
- For Total Assets, as of Sep 2025, the value is 349.00 Cr.. The value appears strong and on an upward trend. It has increased from 336.00 Cr. (Mar 2025) to 349.00 Cr., marking an increase of 13.00 Cr..
However, the Borrowings (155.00 Cr.) are higher than the Reserves (62.00 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -33.00 | -32.00 | -74.00 | -78.00 | -93.00 | -106.00 | -113.00 | -85.00 | -80.00 | -106.00 | -109.00 | -120.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 93 | 88 | 105 | 99 | 111 | 105 | 106 | 98 | 98 | 113 | 107 | 111 |
| Inventory Days | 122 | 132 | 145 | 172 | 240 | 217 | 292 | 146 | 162 | 207 | 167 | 238 |
| Days Payable | 129 | 142 | 163 | 171 | 182 | 147 | 167 | 114 | 143 | 167 | 147 | 189 |
| Cash Conversion Cycle | 86 | 78 | 87 | 100 | 168 | 175 | 231 | 130 | 117 | 153 | 127 | 161 |
| Working Capital Days | 11 | 14 | 50 | 26 | 45 | 25 | -11 | 11 | 18 | 13 | 12 | 6 |
| ROCE % | 11% | 7% | 8% | 8% | 7% | -0% | 10% | 12% | 10% | 12% | 10% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 4.54 | 4.94 | 1.67 | 3.79 | 3.34 |
| Diluted EPS (Rs.) | 4.54 | 4.96 | 1.68 | 3.79 | 3.34 |
| Cash EPS (Rs.) | 10.68 | 11.08 | 7.49 | 9.95 | 9.60 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 48.63 | 43.82 | 40.60 | 39.46 | 35.99 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 48.63 | 43.82 | 40.60 | 39.46 | 35.99 |
| Revenue From Operations / Share (Rs.) | 190.37 | 214.64 | 193.89 | 189.72 | 169.02 |
| PBDIT / Share (Rs.) | 19.95 | 21.75 | 16.61 | 19.31 | 17.27 |
| PBIT / Share (Rs.) | 13.81 | 15.38 | 10.79 | 13.21 | 10.85 |
| PBT / Share (Rs.) | 3.23 | 5.72 | 3.03 | 6.20 | 2.77 |
| Net Profit / Share (Rs.) | 4.54 | 4.71 | 1.67 | 3.85 | 3.18 |
| NP After MI And SOA / Share (Rs.) | 4.53 | 4.68 | 1.64 | 3.79 | 3.20 |
| PBDIT Margin (%) | 10.47 | 10.13 | 8.56 | 10.18 | 10.21 |
| PBIT Margin (%) | 7.25 | 7.16 | 5.56 | 6.96 | 6.41 |
| PBT Margin (%) | 1.69 | 2.66 | 1.56 | 3.26 | 1.63 |
| Net Profit Margin (%) | 2.38 | 2.19 | 0.86 | 2.02 | 1.88 |
| NP After MI And SOA Margin (%) | 2.38 | 2.17 | 0.84 | 1.99 | 1.89 |
| Return on Networth / Equity (%) | 9.32 | 10.66 | 4.03 | 9.57 | 8.85 |
| Return on Capital Employeed (%) | 18.92 | 20.86 | 16.30 | 20.64 | 18.36 |
| Return On Assets (%) | 2.14 | 2.31 | 0.82 | 2.15 | 1.97 |
| Long Term Debt / Equity (X) | 0.40 | 0.52 | 0.47 | 0.46 | 0.44 |
| Total Debt / Equity (X) | 1.94 | 2.01 | 2.05 | 1.67 | 1.95 |
| Asset Turnover Ratio (%) | 0.92 | 1.07 | 1.06 | 1.12 | 0.99 |
| Current Ratio (X) | 1.07 | 1.15 | 1.09 | 1.11 | 1.08 |
| Quick Ratio (X) | 0.60 | 0.72 | 0.62 | 0.66 | 0.68 |
| Inventory Turnover Ratio (X) | 3.18 | 1.95 | 2.08 | 2.43 | 2.12 |
| Dividend Payout Ratio (NP) (%) | 26.47 | 21.22 | 60.55 | 26.41 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 11.24 | 8.98 | 13.30 | 10.11 | 0.00 |
| Earning Retention Ratio (%) | 73.53 | 78.78 | 39.45 | 73.59 | 0.00 |
| Cash Earning Retention Ratio (%) | 88.76 | 91.02 | 86.70 | 89.89 | 0.00 |
| Interest Coverage Ratio (X) | 1.88 | 2.25 | 2.14 | 2.75 | 2.14 |
| Interest Coverage Ratio (Post Tax) (X) | 1.43 | 1.49 | 1.21 | 1.55 | 1.39 |
| Enterprise Value (Cr.) | 274.72 | 270.49 | 228.31 | 252.09 | 180.34 |
| EV / Net Operating Revenue (X) | 0.90 | 0.79 | 0.75 | 0.89 | 0.71 |
| EV / EBITDA (X) | 8.65 | 7.87 | 8.76 | 8.81 | 7.05 |
| MarketCap / Net Operating Revenue (X) | 0.43 | 0.42 | 0.34 | 0.56 | 0.31 |
| Retention Ratios (%) | 73.52 | 78.77 | 39.44 | 73.58 | 0.00 |
| Price / BV (X) | 1.71 | 2.08 | 1.65 | 2.73 | 1.49 |
| Price / Net Operating Revenue (X) | 0.43 | 0.42 | 0.34 | 0.56 | 0.31 |
| EarningsYield | 0.05 | 0.05 | 0.02 | 0.03 | 0.05 |
After reviewing the key financial ratios for Bal Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 4.54. This value is below the healthy minimum of 5. It has decreased from 4.94 (Mar 24) to 4.54, marking a decrease of 0.40.
- For Diluted EPS (Rs.), as of Mar 25, the value is 4.54. This value is below the healthy minimum of 5. It has decreased from 4.96 (Mar 24) to 4.54, marking a decrease of 0.42.
- For Cash EPS (Rs.), as of Mar 25, the value is 10.68. This value is within the healthy range. It has decreased from 11.08 (Mar 24) to 10.68, marking a decrease of 0.40.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 48.63. It has increased from 43.82 (Mar 24) to 48.63, marking an increase of 4.81.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 48.63. It has increased from 43.82 (Mar 24) to 48.63, marking an increase of 4.81.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 190.37. It has decreased from 214.64 (Mar 24) to 190.37, marking a decrease of 24.27.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 19.95. This value is within the healthy range. It has decreased from 21.75 (Mar 24) to 19.95, marking a decrease of 1.80.
- For PBIT / Share (Rs.), as of Mar 25, the value is 13.81. This value is within the healthy range. It has decreased from 15.38 (Mar 24) to 13.81, marking a decrease of 1.57.
- For PBT / Share (Rs.), as of Mar 25, the value is 3.23. This value is within the healthy range. It has decreased from 5.72 (Mar 24) to 3.23, marking a decrease of 2.49.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 4.54. This value is within the healthy range. It has decreased from 4.71 (Mar 24) to 4.54, marking a decrease of 0.17.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 4.53. This value is within the healthy range. It has decreased from 4.68 (Mar 24) to 4.53, marking a decrease of 0.15.
- For PBDIT Margin (%), as of Mar 25, the value is 10.47. This value is within the healthy range. It has increased from 10.13 (Mar 24) to 10.47, marking an increase of 0.34.
- For PBIT Margin (%), as of Mar 25, the value is 7.25. This value is below the healthy minimum of 10. It has increased from 7.16 (Mar 24) to 7.25, marking an increase of 0.09.
- For PBT Margin (%), as of Mar 25, the value is 1.69. This value is below the healthy minimum of 10. It has decreased from 2.66 (Mar 24) to 1.69, marking a decrease of 0.97.
- For Net Profit Margin (%), as of Mar 25, the value is 2.38. This value is below the healthy minimum of 5. It has increased from 2.19 (Mar 24) to 2.38, marking an increase of 0.19.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 2.38. This value is below the healthy minimum of 8. It has increased from 2.17 (Mar 24) to 2.38, marking an increase of 0.21.
- For Return on Networth / Equity (%), as of Mar 25, the value is 9.32. This value is below the healthy minimum of 15. It has decreased from 10.66 (Mar 24) to 9.32, marking a decrease of 1.34.
- For Return on Capital Employeed (%), as of Mar 25, the value is 18.92. This value is within the healthy range. It has decreased from 20.86 (Mar 24) to 18.92, marking a decrease of 1.94.
- For Return On Assets (%), as of Mar 25, the value is 2.14. This value is below the healthy minimum of 5. It has decreased from 2.31 (Mar 24) to 2.14, marking a decrease of 0.17.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.40. This value is within the healthy range. It has decreased from 0.52 (Mar 24) to 0.40, marking a decrease of 0.12.
- For Total Debt / Equity (X), as of Mar 25, the value is 1.94. This value exceeds the healthy maximum of 1. It has decreased from 2.01 (Mar 24) to 1.94, marking a decrease of 0.07.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.92. It has decreased from 1.07 (Mar 24) to 0.92, marking a decrease of 0.15.
- For Current Ratio (X), as of Mar 25, the value is 1.07. This value is below the healthy minimum of 1.5. It has decreased from 1.15 (Mar 24) to 1.07, marking a decrease of 0.08.
- For Quick Ratio (X), as of Mar 25, the value is 0.60. This value is below the healthy minimum of 1. It has decreased from 0.72 (Mar 24) to 0.60, marking a decrease of 0.12.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.18. This value is below the healthy minimum of 4. It has increased from 1.95 (Mar 24) to 3.18, marking an increase of 1.23.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 26.47. This value is within the healthy range. It has increased from 21.22 (Mar 24) to 26.47, marking an increase of 5.25.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 11.24. This value is below the healthy minimum of 20. It has increased from 8.98 (Mar 24) to 11.24, marking an increase of 2.26.
- For Earning Retention Ratio (%), as of Mar 25, the value is 73.53. This value exceeds the healthy maximum of 70. It has decreased from 78.78 (Mar 24) to 73.53, marking a decrease of 5.25.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 88.76. This value exceeds the healthy maximum of 70. It has decreased from 91.02 (Mar 24) to 88.76, marking a decrease of 2.26.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 1.88. This value is below the healthy minimum of 3. It has decreased from 2.25 (Mar 24) to 1.88, marking a decrease of 0.37.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.43. This value is below the healthy minimum of 3. It has decreased from 1.49 (Mar 24) to 1.43, marking a decrease of 0.06.
- For Enterprise Value (Cr.), as of Mar 25, the value is 274.72. It has increased from 270.49 (Mar 24) to 274.72, marking an increase of 4.23.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.90. This value is below the healthy minimum of 1. It has increased from 0.79 (Mar 24) to 0.90, marking an increase of 0.11.
- For EV / EBITDA (X), as of Mar 25, the value is 8.65. This value is within the healthy range. It has increased from 7.87 (Mar 24) to 8.65, marking an increase of 0.78.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.43. This value is below the healthy minimum of 1. It has increased from 0.42 (Mar 24) to 0.43, marking an increase of 0.01.
- For Retention Ratios (%), as of Mar 25, the value is 73.52. This value exceeds the healthy maximum of 70. It has decreased from 78.77 (Mar 24) to 73.52, marking a decrease of 5.25.
- For Price / BV (X), as of Mar 25, the value is 1.71. This value is within the healthy range. It has decreased from 2.08 (Mar 24) to 1.71, marking a decrease of 0.37.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.43. This value is below the healthy minimum of 1. It has increased from 0.42 (Mar 24) to 0.43, marking an increase of 0.01.
- For EarningsYield, as of Mar 25, the value is 0.05. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.05.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Bal Pharma Ltd:
- Net Profit Margin: 2.38%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 18.92% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 9.32% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.43
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.6
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 16.1 (Industry average Stock P/E: 50.55)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 1.94
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 2.38%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | # 21 & 22, Bengaluru Karnataka 560099 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Shailesh D Siroya | Managing Director |
| Mr. Himesh Virupakshaya | Executive Director |
| Mr. Ravindrakumar Kothari | Non Executive Director |
| Mr. Jatish Sheth | Independent Director |
| Ms. Nicloa Neeladri | Independent Director |
| Mr. H S Venkatesh | Independent Director |
FAQ
What is the intrinsic value of Bal Pharma Ltd?
Bal Pharma Ltd's intrinsic value (as of 21 January 2026) is ₹63.89 which is 6.46% lower the current market price of ₹68.30, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹110 Cr. market cap, FY2025-2026 high/low of ₹129/67.2, reserves of ₹62 Cr, and liabilities of ₹349 Cr.
What is the Market Cap of Bal Pharma Ltd?
The Market Cap of Bal Pharma Ltd is 110 Cr..
What is the current Stock Price of Bal Pharma Ltd as on 21 January 2026?
The current stock price of Bal Pharma Ltd as on 21 January 2026 is ₹68.3.
What is the High / Low of Bal Pharma Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Bal Pharma Ltd stocks is ₹129/67.2.
What is the Stock P/E of Bal Pharma Ltd?
The Stock P/E of Bal Pharma Ltd is 16.1.
What is the Book Value of Bal Pharma Ltd?
The Book Value of Bal Pharma Ltd is 49.2.
What is the Dividend Yield of Bal Pharma Ltd?
The Dividend Yield of Bal Pharma Ltd is 1.76 %.
What is the ROCE of Bal Pharma Ltd?
The ROCE of Bal Pharma Ltd is 10.1 %.
What is the ROE of Bal Pharma Ltd?
The ROE of Bal Pharma Ltd is 9.66 %.
What is the Face Value of Bal Pharma Ltd?
The Face Value of Bal Pharma Ltd is 10.0.